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Abstract
In a recent analysis of metabolic scaling in solid tumours we found a scaling law
that interpolates between the power laws µ ∝ V and µ ∝ V 2/3, where µ is the
metabolic rate expressed as the glucose absorption rate and V is the tumour
volume. The scaling law fits quite well both in vitro and in vivo data, however we
also observed marked fluctuations that are associated with the specific biological
properties of individual tumours. Here we analyse these fluctuations, in an
attempt to find the population-wide distribution of an important parameter
(A) which expresses the total extent of the interface between the solid tumour
and the non-cancerous environment. Heuristic considerations suggest that the
values of the A parameter follow a lognormal distribution, and, allowing for the
large uncertainties of the experimental data, our statistical analysis confirms
this.
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1. Introduction
The allometric laws of biology are power laws that describe in simple and
universal terms some of the features that are common to the vast diversity of
living organisms [1, 2, 3]. Their simplicity hides the ambitious aim of encap-
sulating in a single equation the huge variability and diverse dynamics that5
belong to living systems. Sometimes, their purely empirical character has pro-
duced controversy, and some of these laws are not universally accepted [4, 5, 6].
Kleiber’s law is one such scaling law: it states that the basal metabolic rate of
an organism of mass M scales as M3/4 = M0.75 [7]instead of the naive estimate
M2/3 ≈M0.67, and it has both supporters and opponents. Kleber’s law has long10
been mysterious and only in recent years it has found the backing of a biological
argument based on fractal structure of microcirculation [8], which is however
still controversial [9, 10, 11, 11]. Nonetheless, the law has been applied also
outside the domain of validity of the supporting argument, as in the case of the
metabolism of solid tumours [12]. Indeed, microcirculation in tumour tissues15
is quite different from normal tissues, with an ensuing wide-ranging variability
of cellular phenotypes and local microenvironments. However, it is well-known
that there is a strong correlation between tumour microenvironment and aggres-
siveness, and this provides a strong motivation to study the microscopic origin
of any metabolic scaling law that may arise in this context.20
We have recently proposed a metabolic scaling law for solid tumours that
describes quite well both in vitro and in vivo experimental data (see figure 1)
[13]. Its peculiarity is that it has been obtained with the help of a computational
description of metabolism at the single-cell level which provides the link with
the microscopic features of tumours [14, 15, 16]. The law is not quite a power
law, and it is given by the following expression:
µ =
(
c
vc
)
3λV
3λ+ (V/A)1/3
(1)
where µ is the metabolic rate expressed as the glucose absorption rate, V is the
tumour volume, vc is the mean cell volume, c is the cell-specific consumption rate
2
- -- -
- --
---- - -
- - -
--
- -- -
- --
---- - -
- - -
--
- -
-
-
- -
-
--
-
- -
- -
- -
- -
-
-
-
- - -
● ●● ●● ●●
●●●● ●●●●
●●●
● ● ●
●
● ●
● ●
● ● ●
●eq. (3)(V/A)
3λ(V/A)2/3
��� ��� ��� ��� ����
���
���
���
���
�/� (μ��)
μ �(μ�
� )
--
--------
------
----- --
--
- ---- -
--
------ --
- - -
--
--------
------
----- --
--
- ---- -
--
------ --
- - -
●●
●●●●●●●●●●●●●●● ●●●
●● ●●●●●●●●●●●●●
●●●
eq. (3)(V/A)
3λ(V/A)2/3
��� ��� ��� ��� ����
���
���
���
���
�/� (μ��)
μ �(μ�
� )
Figure 1: Metabolic rate data µˆN = µ/ηA
1/3 vs. V/A(µm3). The figure shows a breakdown
of the data originally presented in [13]. Upper panel: tumor spheroids cultured in vitro using
different cell lines. Lower panel: data from human tumours, that include breast, uterine and
ovarian carcinomas, melanomas, thyroid carcinomas, colon and lung carcinomas. All of these
human tumours correspond presumably to different cell-specific metabolic rates η. The dotted
line is µˆN = V , while the dashed line is µˆN = V
2/3, which are the extreme behaviours derived
from equation (1).
of a single cell [13], and A is a non-dimensional parameter whose meaning will
be clarified below. The λ parameter is a characteristic length in an exponential
law that describes the decay of the fraction of live cells with increasing distance
from the blood vessels (see [16] for details). The ratio η = c/vc in equation (1) is
independent of cell size, since c is roughly proportional to cell volume. Equation
(1) shows that the metabolic rate interpolates between the two power-laws
µ ≈
(
c
vc
)
V (2)
3
at small volume and
µ ≈
(
c
vc
)
3λ
(3/4pi)
1/3
V 2/3 (3)
at large volume, and if we take the middle value of the exponent (0.84) we note
that it is not very far from the exponent of Kleiber’s law.
Turning to parameter A, we note that is related to the total extent of the
interface between solid tumour and surrounding environment, see fig.2: if x is
a diameter (chosen between two recognizable features of the tumour) then the25
total interface area S scales as S = Ax2 (see also ref [13] ). The analysis of
existing data – both in vitro and in vivo – points to a strong dependence of the
metabolic rate on A. In particular, we attribute the spread of data about the
theoretical expression shown in figure 1 to the fluctuations of A in populations
of histologically similar tumours. Since the interface area of a tumour with the30
normal tissue environment influences both its growth rate and its metastatic
potential, these fluctuations are clinically relevant.
In this paper we argue that the probability distribution of A is lognormal, and
we show that the experimental data support this conjecture.
2. Theory35
The A parameter is directly related to the complexity of the interface be-
tween tumour and environment (see figure 2), and the interface growth can be
pictured as a gradual buildup of new features that appear on already existing el-
ements, in a way that is multiplicative rather than additive – as in a Kolmogorov
process [17]. Such a process has already been assumed in simple simulations of
biological growth based on analogs of diffusion limited aggregation [18, 19], and
if growth can be mapped on a Kolmogorov process this leads to a lognormal
distribution [17, 20, 21]
p(A;m,σ) =
1
A
√
2piσ2
exp
[
− (lnA−m)
2σ2
2
]
(4)
where m and σ are the parameters that define the shape of the distribution.
This type of growth has already been used in an attempt to explain the complex
4
structure of human lungs [22]. In this section we demonstrate the plausibility
of the lognormal conjecture and show how to obtain values of A from the data
shown in figure 1.40
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Figure 2: Schematic view of the tumour-environment interface in solid tumours and in tumour
spheroids. 1. Cross section of a solid tumour at low magnification. Live tumour cells (T) wrap
around blood vessels (BV) to form tumour cords. Because of the limited diffusion of nutrients,
tumour cells that are distant from blood vessels die and become necrotic (N). 2. Enlarged
view of a single tumour cord. The density of live cells decreases at increasing distance from
blood vessels as dead cells mix with live cells. 3. A multicellular tumour spheroid (MTS) – an
important in vitro model of avascular tumours – surrounded by culture medium (M) at low
magnification. Live tumour cells (T) proliferate in the external layers, while dead cells form
a necrotic core (N). 4. Enlarged view of the MTS section shown in 3: live cells mix with dead
cells just as in real tumours. In both real tumours and MTS live cells wrap and fold around
the nutrient supply system, i.e. blood vessels and the external environment, respectively. The
value of A is determined by the interface between the bulk of the living tumour cells and
the non cancerous environment, and this includes the network of blood vessels that supply
the tumour with nutrients. Therefore A is expected to be much higher in vascularised solid
tumours than in avascular tumour spheroids.
5
2.1. The distribution of the A parameter
Figure 2 contains two classes of solid tumours: solid tumours in vivo and
tumour spheroids in vitro, and we consider the lognormal arguments separately
for each class.
2.1.1. The case of in vivo solid tumours45
In this case the conjecture that the A parameter follows a lognormal dis-
tribution is made plausible by the following considerations. In a solid tumour
with total volume V and total interface area S, the interface corresponds to
all the surface where tumour cells exchange oxygen, nutrients and metabolites
with the environment, and can be identified with the set of blood vessels that
traverse the tumour mass. This corresponds to a large area, and if we make
the simplifying assumption that the radius r of blood vessels is fixed, then it
is given by S ≈ 2pirL, where L is the total length of the blood vessel network.
When the linear size of the volume increases by a factor α, we find that the
volume increases by a factor α3 and the surface area by a factor α2, however
this also means that the total length of the blood vessel network also increases
by the same factor α2. This tells us that blood vessels sprout new vessels, and
the contribution of these new blood vessels to the total network length is the
difference between the quadratic growth and a simpler linear growth
α2L− αL = αL(α− 1) (5)
The same reasoning works also in the more general case where the growth of the
interface area is not exactly quadratic, but has a fractional exponent S′ = αβS,
then the contribution of new vessels to the growth of the network length is
αβL− αL = αL(αβ−1 − 1) (6)
Whatever the case, there cannot be a continuos growth, and the evolution of the
tumour mass must be punctuated by discrete sprouting events, with a random
distribution of α at each step. We can also write
S =
dV
dx
=
d(α3V0)
d(αx0)
= 3α2
V0
x0
= 3α2A0x
2
0 (7)
6
in the case of growth over many sprouting events, where subscripted values are
fixed at a given time t0, or also
S =
dVn+1
dx
=
d(α3n+1Vn)
d(αn+1xn)
= 3α2n+1
Vn
xn
= 3α2n+1Anx
2
n (8)
for growth between two sprouting events. Then we see from this equation that
the actual value of A at any given time fluctuates about an average, and that
it is given by
A = α2A0 =
∏
k
α2kA0 (9)
where α is the combined, multiplicative result of many blood vessel sprouting
events. This means that
lnA = 2
∑
k
lnαk + lnA0 (10)
so that lnA is a (large) sum of variates, and if the assumptions of the central
limit theorem hold, then A has a lognormal distribution.
2.1.2. The case of in vitro tumour spheroids
The previous considerations do not apply to avascular tumours like the tu-
mour spheroids, however we can pinpoint processes that contribute to a sim-50
ilar multiplicative structure in the determination of the actual interface area.
Indeed, it has long been known that tumour spheroids grown in identical con-
ditions can have widely differing sizes at saturation [23, 24], and that this is
closely related with the spheroid structure, in particular with the formation
of the necrotic core: this fact underscores the importance both of the random55
events at the single-cell level – the only difference in the development of these
spheroids – and of the structural elements. Another hint is provided by obser-
vations of the surface of tumour spheroids, which is often rough and marked by
hills and valleys; this fact has recently been exploited in a study of the delivery
of nanoparticles into tumour tissue [25]. Irregularities such as these are again60
the result of discrete and at least partially random events, like cell death in the
necrotic core and the mitoses in the outer cell layer of tumour spheroids, and
7
the previous reasoning applies again – although we expect to find a lognormal
distribution with different parameters.
2.2. Finding A from metabolic data65
Here we remark that we can use the metabolic scaling law to determine A
when the other parameters are fixed
A ≈ V
(3λ)3(ηV/µ− 1)3 (11)
and we do so both for cultured tumour spheroids, where it is easier to estimate
η, and for human tumours, using an average η. For a given histological type,
both η and λ are nearly fixed, and here we take the values of λ estimated in
[13] for tumour spheroids and for human tumours. Because of the difficulty of
obtaining valid data, we also use the same datasets of [13], that we selected70
after an extensive search of the existing literature. And indeed, while there are
many data available, their usability is limited by the following requirements:
• we utilise glucose absorption to define the metabolic rate; therefore all the
data used in equation (1) or (11) must refer to glucose;
• it is difficult to find combined values of the parameters for the same cell75
line;
• we cannot use data expressed in arbitrary units. This rules out many data
like those obtained with uncalibrated imaging techniques, those obtained
with radioactive markers without any indication of the specific activity
of labelled compounds, and data normalised per gram of tumour tissue80
without any reference to the total amount of tissue used.
3. Calculation
We used the procedure of section 2.2 to obtain the A values corresponding to
the data shown in figure 1. Since these data are affected by rather large uncer-
tainties, the complete probability density function (pdf) of each measurements
8
is the convolution of the lognormal distribution with a normal distribution (we
make the usual assumption that measurement uncertainties have a normal dis-
tribution):
p(A, σ0;m,σ) =∫ A
−∞
1
(A− x)
√
2piσ2
exp
{
− [ln(A− x)−m]
2
2σ2
}
1√
2piσ20
exp
(
− x
2
2σ20
)
dx (12)
where σ0 is the measurement error. Then the complete log-likelihood is
lnL(D;m,σ) =
∑
i
ln p (A(i), σ0(i);m,σ) (13)
where D = {A(i), σ0(i)}i=1,n is the set of all n data values and their mea-
surement errors. The evaluation of the log-likelihood requires the numerical
evaluation of all the individual likelihoods, since expression (12) does not have85
a closed analytical form. The log likelihood (13) is only approximate because
the large measurement errors on A cannot be Gaussian – A is a non-negative
parameter – and moreover it depends strongly on the specific measurement er-
rors σ0(i). Moreover, we have only incomplete information on the measurement
themselves and could not obtain good error estimates for many datapoints. All90
of this leads to large numerical uncertainties and to inconclusive results when
using the log-likelihood (13), so that eventually we opted to fit the values A
deduced with (11) with the lognormal pdf (4), and our results are also shown
in figures 3 and 4.
We tested the validity of the lognormal hypothesis by comparing it with95
a highly flexible phenomenological model, a Gaussian mixture model with a
variable number of components. We did this in a Bayesian framework, and we
ranked the different hypotheses using marginal likelihoods, both for cultured
spheroids and for solid tumours.
In the case of cultured spheroids we considered a total of 35 alternative100
models, the lognormal model and 34 Gaussian mixture models with a number
of components ranging from 1 to 34. We defined only 34 mixture models because
the data set contains 34 samples, and therefore any more complex model would
9
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Figure 3: Pdf of the values of A in the case of the aggregated tumour spheroid data (spheroids
from the 9L, MR1 and Rat-T1 cell lines): the original data points are shown as a “rug plot”
(the positions marked by the vertical bars in the lower part of the plot). In addition to the
glucose uptake values given in [13] we have used η = 6.5 × 10−12 and λ = 93.9 µm for 9L
spheroids, η = 4.2 × 10−12 and λ = 123.6;µm for Rat-T1 spheroids; η = 8.9 × 10−12 and
λ = 91.0 µm for MR1 spheroids. The solid curve is the lognormal fit, the dashed line is the
empirical smoothed kernel density, and the dotted line is a power-law with exponent -1.3.
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Figure 4: Pdf of the values of A in the case of human solid tumours: the original data points
are shown as a “rug plot” (the positions marked by the vertical bars in the lower part of the
plot). In addition to the glucose uptake values given in [13] we have used η = 3.7×10−12 and
λ = 99.4 µm. The solid curve is the lognormal fit, the dashed line is the empirical smoothed
kernel density, and the dotted line is a power-law with exponent -1.3.
certainly be less plausible than the one with 34 components. Thus, we have the
following likelihoods for individual data samples:105
10
Lognormal model.
p(A|m,σ) = logN(A;m,σ) (14)
Model 1.
p(A|θ) =
1∑
i=1
αnN(A;mi, σi) θ = (α1,m1, σ1) (15)
. . .
Model 34.
p(A|θ) =
34∑
i=1
αnN(A;mi, σi) θ = ({αi}i=1,34, {mi}i=1,34, {σi}i=1,34) (16)
where logN(A;m,σ) is the lognormal pdf with parameters m and σ as above,
and N(A;m,σ) is the normal pdf with parameters m and σ.
We introduced weakly informative priors for these models. For the lognormal
one, m and σ were assigned uniform priors from 0 to 200. For the mixture models110
of M components, we assigned M − 1 uniform priors for αi in the interval 0 to
1, added an extra improper prior for
∑M−1
i=1 αi < 1, define αM = 1−
∑M−1
i=1 αi,
assigned all mi and σi to be independent and uniformly distributed from 0 to
200, and finally we added an improper prior for m1 ≤ m2 ≤ · · · ≤ mM .
To rank alternative hypotheses, we need to estimate marginal likelihoods115
for the alternative models. We estimated these likelihoods using the Thermo-
dynamic Integration method proposed by [26], and obtained the results shown
in figure 5. Together with the Bayes factor for preferring the lognormal model
over any of the mixture models having the value of 4.45 × 1018, this indicates
decisive evidence that the lognormal model should be preferred over any mix-120
ture of Gaussians. Our solid tumour dataset has just as many samples as the
tumour spheroid dataset and we repeated the same kind of analysis; we used
uniform priors from 0 to 200000 for the m’s and σ’s, since we expect a wider
range of A. In this case the lognormal hypothesis ranks only second (see figure
6), however we note that the solid tumour data are much more dependent on125
the assumptions of metabolic consumption rate, etc., and therefore they carry
11
with them potentially large systematic errors. Moreover, the Gaussian mixture
model is purely phenomenological and does not rely on laws of scaling in Bi-
ology. The better performance of this mixture model can be explained by its
relative simplicity while preserving good flexibility for matching experimental130
data. Notice that the lognormal model fares better than the large majority of
the highly flexible Gaussian mixture models and in contrast to all of them it is
biologically motivated.
2 VLAD VYSHEMIRSKY
and  i to be independent and uniformly distributed from 0 to 200, finally, we add
an improper order prior for µ1  µ2  . . .  µM .
2. Estimating Marg nal Likeli oods
To rank alt rnative hypotheses, we need to estimate marginal l kelihoods for
the alternative models. We estimated these likelihoods using the Thermodynamic
Integration method proposed by (N. Friel et al., 2008), and obtained the results
listed in Table 1. These results produce relative model probabilities as depicted in
the following chart:
Together with the Bayes factor for preferring the log-normal model over any
of the mixture models having the value of 4.448077 ⇥ 1018, this indicates deci-
sive evidence that the log-Normal model should be preferred over any mixture of
gaussians.
3. References
N. Friel, and A. N. Pettitt, 2008, Marginal likelihood estimation via
power posteriors, Journal of the Royal Statistical Society: Series B, 70(3),
589 – 607.
Figure 5: Ranking of hypotheses in the case of in vitro tumour spheroids. The numbers on
the x ax s m an the number of mixture co ponents, the y axis is the valu of th marginal
likelihood.
4. Results and Discussion
As noted above, the A parameter is related to the overall shape of the tu-135
mour. It is one of the factors that set the timescale of tumour growth and has an
importance of its own, as it determines both the total tumour volume and the
size of the interface between tumour and nutrient-supplying blood vessels. This
interface also regulates the influx of drugs and influences the overall metastatic
potential because it is the place where tumour cells can enter the blood stream.140
The heuristic considerations discussed above suggest that tumour spheroids and
12
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Figure 6: Ranking of hypotheses in the case of solid tumours in vivo. The numbers on the
x axis mean the number of mixture components, the y axis is the value of the marginal
likelihood.
solid tumours in vivo both have lognormal distributions, although with differ-
ent parameters. The actual observations indicate that the distinction is correct,
and show that the A parameter becomes quite large in vascularised tumours in
vivo because of the fractal nature of the capillary network that feeds tumours145
[27]. The statistical analysis lends a support to the lognormal conjecture that
is strong in the case of in vitro tumors, but it is still inconclusive for in vivo
tumours and a compelling statement requires additional data.
Interestingly, when the σ parameter is smaller than m the tail of the lognor-
mal distribution provides a reasonable approximation of a power-law distribu-150
tion over several orders of magnitude, a fact that has prompted [20, 21] to argue
that the ubiquitous power-law distributions may actually stem from underlying
lognormals. If this turned out to be true also in this case, then in a certain
subrange of values the A parameter would display a sort of scale invariance over
the population of solid tumours – this is also illustrated in figures 3 and 4 where155
we plotted a power law ∼ 1/A1.3 ≈ 1/A4/3 to show the kind of scale-invariance
13
that we would obtain with the present data analysis.
4.1. Conclusions
The A parameter sets the extent of the interface area, and for this reason it
has an obvious correlation with tumour aggressiveness and with the structure of160
the tumour microenvironment, and a detailed knowledge of its distribution can
yield important statistical estimates on the overall behaviour of a population of
solid tumours. This requires a protocol for measuring A in a large number of
cases, and we expect that studies of A for different histological tumour types
can lead to different parameter sets. Finally, the global statistical parameters165
could be used to assess the eventual prognosis with a given dynamics of A in an
individual tumour.
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